Fate Therapeutics (FATE) Enterprise Value (2016 - 2025)
Fate Therapeutics' Enterprise Value history spans 14 years, with the latest figure at -$203.7 million for Q4 2025.
- For Q4 2025, Enterprise Value rose 27.02% year-over-year to -$203.7 million; the TTM value through Dec 2025 reached -$203.7 million, up 27.02%, while the annual FY2025 figure was -$203.7 million, 27.02% up from the prior year.
- Enterprise Value reached -$203.7 million in Q4 2025 per FATE's latest filing, up from -$215.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$203.7 million in Q4 2025 to a low of -$790.1 million in Q1 2021.
- Average Enterprise Value over 5 years is -$423.1 million, with a median of -$380.7 million recorded in 2023.
- Peak YoY movement for Enterprise Value: plummeted 288.69% in 2021, then soared 37.31% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$615.9 million in 2021, then grew by 29.17% to -$436.2 million in 2022, then grew by 27.75% to -$315.2 million in 2023, then increased by 11.46% to -$279.1 million in 2024, then grew by 27.02% to -$203.7 million in 2025.
- Per Business Quant, the three most recent readings for FATE's Enterprise Value are -$203.7 million (Q4 2025), -$215.4 million (Q3 2025), and -$222.8 million (Q2 2025).